Rilotumumab Completed Phase 2 Trials for Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Recurrent Fallopian Tube Carcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01039207Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer